NBIX vs. VTRS: Neurocrine Biosciences vs. Viatris Stock Comparison
How do Neurocrine Biosciences (NBIX) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Neurocrine Biosciences (NBIX) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while VTRS is classified in Pharmaceuticals.
| Profile Item | NBIX | VTRS |
|---|---|---|
| Name | Neurocrine Biosciences, Inc. | Viatris Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 16.66 billion USD | 22.83 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 23, 1996 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | NBIX | VTRS |
|---|---|---|
| Total Return (1Y) | 9.40% | 108.98% |
| Total Return (3Y, Annualized) | 14.12% | 36.75% |
| Total Return (5Y, Annualized) | 12.61% | 11.59% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | NBIX | VTRS |
|---|---|---|
| Volatility (1Y, Annualized) | 35.05% | 32.53% |
| Beta (5Y) | 0.29 | 0.86 |
| Max Drawdown (5Y) | -42.89% | -45.69% |
| Avg. Volume (3M) | 1.31M | 8.87M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | NBIX | VTRS |
|---|---|---|
| Sharpe Ratio (1Y) | 0.15 | 3.22 |
| Sortino Ratio (1Y) | 0.22 | 5.63 |
Profitability
ROE (TTM)
Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Neurocrine Biosciences (NBIX) reports 20.42%, ranking against industry peers normally.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.42%
- Max
- 109.18%
- NBIX
- 20.42%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.21%
- Max
- 109.18%
- Q3
- 6.23%
- VTRS
- -4.21%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Neurocrine Biosciences (NBIX) reports 18.98%, ranking against industry peers normally.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.98%
- NBIX
- 18.98%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.13%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- VTRS
- -4.13%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Neurocrine Biosciences (NBIX) at 31.98% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.98%
- Max
- 83.12%
- NBIX
- 31.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.85%
- Max
- 83.12%
- Q3
- 14.77%
- VTRS
- 13.85%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | NBIX | VTRS |
|---|---|---|
| ROE (TTM) | 20.42% | -4.21% |
| ROA (TTM) | 12.45% | 2.91% |
| Net Margin (TTM) | 18.98% | -4.13% |
| Operating Margin (TTM) | 31.98% | 13.85% |
| Gross Margin (TTM) | 64.67% | 41.13% |
Growth
Revenue Growth
Neurocrine Biosciences (NBIX) at 21.45% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Neurocrine Biosciences (NBIX) reports EPS growth of 41.95%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.
Growth Metrics
| Metric | NBIX | VTRS |
|---|---|---|
| Revenue Growth (YoY) | 21.45% | -2.98% |
| Revenue Growth (3Y CAGR) | 24.32% | -4.20% |
| EPS Growth (YoY) | 41.95% | -- |
| EPS Growth (3Y CAGR) | 44.12% | -- |
Financial Strength
Current Ratio (MRQ)
Both Neurocrine Biosciences (NBIX) at 2.04 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.04
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NBIX
- 2.04
- Min
- 0.10
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VTRS
- 1.55
- Min
- 0.10
Debt / Equity (MRQ)
Neurocrine Biosciences (NBIX) at 0.12 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.12
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NBIX
- 0.12
- Q1
- 0.02
- Min
- 0.00
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.99
- Max
- 1.42
- VTRS
- 0.99
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | NBIX | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 2.04 | 1.55 |
| Debt / Equity (MRQ) | 0.12 | 0.99 |
| Net Debt / EBITDA | -0.27 | 2.64 |
Dividends
Dividend Yield (TTM)
Neurocrine Biosciences (NBIX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.53%
- VTRS
- 2.53%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%).
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
960.00%
- VTRS
- 960.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | NBIX | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.53% |
| Dividend Payout Ratio (TTM) | 0.00% | 960.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Neurocrine Biosciences (NBIX) trades at 24.43 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.43
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- NBIX
- 24.43
- Q1
- 13.30
- Min
- 0.07
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- VTRS
- --
P/S Ratio (TTM)
Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Neurocrine Biosciences (NBIX) at 4.50 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- NBIX
- 4.50
- Q1
- 3.01
- Min
- 0.01
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- VTRS
- 1.55
- Min
- 0.01
P/B Ratio (MRQ)
Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Neurocrine Biosciences (NBIX) at 4.30 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.30
- Max
- 13.53
- Q3
- 6.54
- NBIX
- 4.30
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- VTRS
- 1.67
- Min
- -5.59
Valuation Metrics
| Metric | NBIX | VTRS |
|---|---|---|
| P/E Ratio (TTM) | 24.43 | -- |
| P/S Ratio (TTM) | 4.50 | 1.55 |
| P/B Ratio (MRQ) | 4.30 | 1.67 |
| Free Cash Flow Yield (TTM) | 6.11% | 13.84% |